Valentina Vasilyevna Novikova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Valentina Vasilyevna Novikova has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Vladimir Gennad'Yevich Luzhanin
Federal State Budgetary Educational Institution of Higher Education "Perm State Pharmaceutical Academy" of the Ministry of Health of the Russian Federation
6 shared publications - Vladimir L. Gein
Perm State Pharmaceutical Academy of the Ministry of Health of the Russian Federation
6 shared publications - Виталий Олегович Васильев
Пермская государственная фармацевтическая академия
6 shared publications - Nataliya A. Pulina
Пермская государственная фармацевтическая академия
5 shared publications - O. V. Bobrovskaya
Perm State Pharmaceutical Academy, Perm, Russia
5 shared publications - Alekseeva I.V.
Perm State Pharmaceutical Academy
4 shared publications
Latest Publications
- 6 November 2026
- Published by Folium Publishing Company in Химико-фармацевтический журнал
- Vol. 60 (10) , 40-44
4-(гет)арил-3-бромо-N-(гетар-2-ил)-2,4-диоксобутанамиды: синтез и антифунгальная активность
Получены новые 4-(гет)арил-3-бромо-N-(гетар-2-ил)-2,4-диоксобутанамиды и изучена их противогрибковая активность. Определены некоторые закономерности связи «химическое строение — антифунгальная активность». Установлено, что усилению антифунгальной активности способствует наличие 1,3,4-тиадиазольного фрагмента в структуре бутанамидов. Обнаружены соединения, превышающие действие препарата сравнения, в том числе против видов Candida non-albicans, что дает основания для дальнейшего изучения веществ ряда бромированных (гет)ариламидов 4-(гет)арил-2,4-диоксобутановых кислот.
- 6 November 2026
- Published by Folium Publishing Company in Химико-фармацевтический журнал
- Vol. 60 (10) , 40-44
4-(гет)арил-3-бромо-N-(гетар-2-ил)-2,4-диоксобутанамиды: синтез и антифунгальная активность
Получены новые 4-(гет)арил-3-бромо-N-(гетар-2-ил)-2,4-диоксобутанамиды и изучена их противогрибковая активность. Определены некоторые закономерности связи «химическое строение — антифунгальная активность». Установлено, что усилению антифунгальной активности способствует наличие 1,3,4-тиадиазольного фрагмента в структуре бутанамидов. Обнаружены соединения, превышающие действие препарата сравнения, в том числе против видов Candida non-albicans, что дает основания для дальнейшего изучения веществ ряда бромированных (гет)ариламидов 4-(гет)арил-2,4-диоксобутановых кислот.
- Open Access
- 2 October 2026
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
Furanocoumarins of Heracleum sosnowskyi Manden.: contribution to antimicrobial activity
Introduction. Heracleum sosnowskyi Manden. is a dangerous invasive species containing phototoxic furanocoumarins (FCs). Despite their known cytotoxicity, the antimicrobial potential of FCs has been insufficiently studied, and the contribution of FCs to the overall effect of plant extracts, taking into account technological parameters, has not been established. Aim. A comprehensive assessment of the contribution of furanocoumarins to the antimicrobial activity of extraction products from Heracleum sosnowskyi Manden. herb, depending on the nature of the extractant, temperature, and degree of purification. Materials and methods. Ten extraction products were obtained from raw materials collected in Perm Krai, grouped according to the principle "from native raw materials to individual compounds": juice, hexane extracts (with and without heating), petroleum ether extract, alcohol extracts from defatted raw materials, a total FC fraction, and three enriched fractions (xanthotoxin + psoralen, angelicin + bergapten, angelicin + psoralen + bergapten). The composition was analyzed by TLC and HPLC. Antimicrobial activity was determined against Staphylococcus aureus , Escherichia coli , and Candida albicans using the microdilution method. Results and discussion. HPLC analysis revealed significant differences in the FC profiles. The juice contained a minimum of FCs (~6 %) and was inactive (MIC > 5000 μg/mL). Alcohol extracts from defatted raw materials (FC content 34–60 %) showed low activity (MIC 2500–5000 μg/mL). Lipophilic extracts (hexane, petroleum ether) were characterized by high FC content (80–98 %) and moderate activity (MIC 625–2500 μg/mL); heating during hexane extraction increased the proportion of angelicin and activity against Escherichia coli . The total FC fraction (96 % FC, predominance of angelicin) exhibited high activity (MIC 625–1250 μg/mL). The enriched fractions demonstrated the highest efficacy (MIC 62.5–250 μg/mL), with the three-component mixture (angelicin + psoralen + bergapten) outperforming binary mixtures, indicating synergism. Conclusion. Furanocoumarins are the main carriers of antimicrobial activity in Heracleum sosnowskyi Manden. extracts. Polar components (pigments) make a minor contribution. Extraction efficiency depends on the method: heating with hexane and the use of petroleum ether (a cost-effective alternative) ensure maximum recovery of active FCs. The purified total FC fraction and enriched fractions, especially the three-component one, represent promising candidates for further development of antimicrobial drugs.
- 2 October 2026
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
Open AccessFuranocoumarins of Heracleum sosnowskyi Manden.: contribution to antimicrobial activity
Introduction. Heracleum sosnowskyi Manden. is a dangerous invasive species containing phototoxic furanocoumarins (FCs). Despite their known cytotoxicity, the antimicrobial potential of FCs has been insufficiently studied, and the contribution of FCs to the overall effect of plant extracts, taking into account technological parameters, has not been established. Aim. A comprehensive assessment of the contribution of furanocoumarins to the antimicrobial activity of extraction products from Heracleum sosnowskyi Manden. herb, depending on the nature of the extractant, temperature, and degree of purification. Materials and methods. Ten extraction products were obtained from raw materials collected in Perm Krai, grouped according to the principle "from native raw materials to individual compounds": juice, hexane extracts (with and without heating), petroleum ether extract, alcohol extracts from defatted raw materials, a total FC fraction, and three enriched fractions (xanthotoxin + psoralen, angelicin + bergapten, angelicin + psoralen + bergapten). The composition was analyzed by TLC and HPLC. Antimicrobial activity was determined against Staphylococcus aureus , Escherichia coli , and Candida albicans using the microdilution method. Results and discussion. HPLC analysis revealed significant differences in the FC profiles. The juice contained a minimum of FCs (~6 %) and was inactive (MIC > 5000 μg/mL). Alcohol extracts from defatted raw materials (FC content 34–60 %) showed low activity (MIC 2500–5000 μg/mL). Lipophilic extracts (hexane, petroleum ether) were characterized by high FC content (80–98 %) and moderate activity (MIC 625–2500 μg/mL); heating during hexane extraction increased the proportion of angelicin and activity against Escherichia coli . The total FC fraction (96 % FC, predominance of angelicin) exhibited high activity (MIC 625–1250 μg/mL). The enriched fractions demonstrated the highest efficacy (MIC 62.5–250 μg/mL), with the three-component mixture (angelicin + psoralen + bergapten) outperforming binary mixtures, indicating synergism. Conclusion. Furanocoumarins are the main carriers of antimicrobial activity in Heracleum sosnowskyi Manden. extracts. Polar components (pigments) make a minor contribution. Extraction efficiency depends on the method: heating with hexane and the use of petroleum ether (a cost-effective alternative) ensure maximum recovery of active FCs. The purified total FC fraction and enriched fractions, especially the three-component one, represent promising candidates for further development of antimicrobial drugs.
- 17 September 2026
- Published by Folium Publishing Company in Экспериментальная и клиническая фармакология
- Vol. 89 (8) , 24-27
Противогрибковая активность нового соединения – бромированного (гет)ариламида 4-(гет)арил-2,4-диоксобутановой кислоты в условиях биопленки
Изучена противогрибковая активность нового соединения — бромированного (гет)ариламида 4-(гет)арил-2,4-диоксобутановой кислоты в условиях биопленки. Противогрибковый эффект данного вещества в пленочной культуре превышает действие препарата сравнения флуконазола в 2,2 – 4 раза, имея минимальные подавляющие концентрации в биопленке sessile MIC90 31,2 – 125,0 мг/л (штаммы Candida albicans), 125,0 – 500,0 мг/л (штаммы Candida non-albicans) при соответствующих показателях флуконазола 31,2 – 500,0 и 500 и более мг/л. Показана перспективность дальнейшего исследования нового соединения, обладающего более выраженным эффектом в отношении мультирезистентных клинических штаммов Candida non-albicans, чем флуконазол.
- 17 September 2026
- Published by Folium Publishing Company in Экспериментальная и клиническая фармакология
- Vol. 89 (8) , 24-27
Противогрибковая активность нового соединения – бромированного (гет)ариламида 4-(гет)арил-2,4-диоксобутановой кислоты в условиях биопленки
Изучена противогрибковая активность нового соединения — бромированного (гет)ариламида 4-(гет)арил-2,4-диоксобутановой кислоты в условиях биопленки. Противогрибковый эффект данного вещества в пленочной культуре превышает действие препарата сравнения флуконазола в 2,2 – 4 раза, имея минимальные подавляющие концентрации в биопленке sessile MIC90 31,2 – 125,0 мг/л (штаммы Candida albicans), 125,0 – 500,0 мг/л (штаммы Candida non-albicans) при соответствующих показателях флуконазола 31,2 – 500,0 и 500 и более мг/л. Показана перспективность дальнейшего исследования нового соединения, обладающего более выраженным эффектом в отношении мультирезистентных клинических штаммов Candida non-albicans, чем флуконазол.
- 31 May 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- Vol. 20 (5) , 228-233
Dynamics of mycoses prevalence in the Perm Krai for the period 2020–2024
Introduction . Fungal infections continue to be one of the most common pathologies. Monitoring the prevalence of mycoses is necessary for planning the volume of medical care and optimizing treatment approaches, taking into account regional characteristics. Aim . To study the epidemiological characteristics of mycoses of various localizations for the period 2020–2024 in the Perm Krai to identify main trends and optimize treatment approaches. Materials and methods . A retrospective analysis of data from the Territorial Compulsory Medical Insurance Fund of Perm Krai was conducted. Cases of medical care were examined according to ICD-10 codes: B35.0–B35.9 (dermatophytosis), B36.0, B36.8, B36.9 (other superficial mycoses), B37.0–B37.9 (candidiasis). The number of visits in outpatient settings, as well as in day and 24-hour hospital care, was taken into account. Results . A total of 87,064 cases of mycoses in the analyzed groups were registered during the study period. The prevalence of this group of diseases was 593.7–752.6 per 100,000 population. Dermatophytosis (B35) accounted for 64.1% of the total number, candidiasis (B37) – 15.2%. Other superficial mycoses occurred in 20.7% of cases. The number of dermatophytosis cases increased by 28.8% (from 9,555 to 12,308 visits). In the structure of this group, nail mycosis (B35.1) predominates; its share increased from 58.4% to 63.7%. The most pronounced increase was noted for foot mycosis (B35.3) – 61.1%. Among other superficial mycoses (B36), the increase in the number of cases ranged from 37.6% (B36.9) to 86.2% (B36.8). Candidiasis demonstrated a decrease of 22% mainly due to vulvar and vaginal candidiasis (B37.3). At the same time, a number of nosologies (B37.2, B37.9, B37.0) had a peak in visits in 2022. Conclusion. The analyzed epidemiological data indicate a 26.7% increase in the prevalence of mycoses from 2020 to 2024. A significant increase in visits related to dermatophytosis is noted. The obtained data can be used for planning preventive and therapeutic measures in the region, optimizing the distribution of outpatient resources, as well as for rational planning of drug provision for the population of Perm and the Perm Krai with antifungal drugs with the appropriate spectrum of action.
- 31 May 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- Vol. 20 (5) , 228-233
Dynamics of mycoses prevalence in the Perm Krai for the period 2020–2024
Introduction . Fungal infections continue to be one of the most common pathologies. Monitoring the prevalence of mycoses is necessary for planning the volume of medical care and optimizing treatment approaches, taking into account regional characteristics. Aim . To study the epidemiological characteristics of mycoses of various localizations for the period 2020–2024 in the Perm Krai to identify main trends and optimize treatment approaches. Materials and methods . A retrospective analysis of data from the Territorial Compulsory Medical Insurance Fund of Perm Krai was conducted. Cases of medical care were examined according to ICD-10 codes: B35.0–B35.9 (dermatophytosis), B36.0, B36.8, B36.9 (other superficial mycoses), B37.0–B37.9 (candidiasis). The number of visits in outpatient settings, as well as in day and 24-hour hospital care, was taken into account. Results . A total of 87,064 cases of mycoses in the analyzed groups were registered during the study period. The prevalence of this group of diseases was 593.7–752.6 per 100,000 population. Dermatophytosis (B35) accounted for 64.1% of the total number, candidiasis (B37) – 15.2%. Other superficial mycoses occurred in 20.7% of cases. The number of dermatophytosis cases increased by 28.8% (from 9,555 to 12,308 visits). In the structure of this group, nail mycosis (B35.1) predominates; its share increased from 58.4% to 63.7%. The most pronounced increase was noted for foot mycosis (B35.3) – 61.1%. Among other superficial mycoses (B36), the increase in the number of cases ranged from 37.6% (B36.9) to 86.2% (B36.8). Candidiasis demonstrated a decrease of 22% mainly due to vulvar and vaginal candidiasis (B37.3). At the same time, a number of nosologies (B37.2, B37.9, B37.0) had a peak in visits in 2022. Conclusion. The analyzed epidemiological data indicate a 26.7% increase in the prevalence of mycoses from 2020 to 2024. A significant increase in visits related to dermatophytosis is noted. The obtained data can be used for planning preventive and therapeutic measures in the region, optimizing the distribution of outpatient resources, as well as for rational planning of drug provision for the population of Perm and the Perm Krai with antifungal drugs with the appropriate spectrum of action.
- 2 September 2025
- Published by Folium Publishing Company in Экспериментальная и клиническая фармакология
- Vol. 88 (8) , 3-5
Противогрибковая активность этиловых эфиров 2-амино-5-(1-бром-2-арил-2-оксоэтилиден)-4-оксо-1H-4,5-дигидрофуран-3-карбоновых кислот
Изучена противогрибковая активность этиловых эфиров 2-амино-5-(1-бром- 2-арил-2-оксоэтилиден)-4-оксо-1H-4,5-дигидрофуран-3-карбоновых кислот. Установлено, что соединение с 4-хлорфенильным заместителем обладает наиболее выраженным противогрибковым действием (МПК50 — 3,9 мг/л, МПК90 — 7,8 мг/л), что превышает активность флуконазола, в том числе, в отношении Candida auris, что дает основание для дальнейшего изучения данного вещества.
- 2 September 2025
- Published by Folium Publishing Company in Экспериментальная и клиническая фармакология
- Vol. 88 (8) , 3-5
Противогрибковая активность этиловых эфиров 2-амино-5-(1-бром-2-арил-2-оксоэтилиден)-4-оксо-1H-4,5-дигидрофуран-3-карбоновых кислот
Изучена противогрибковая активность этиловых эфиров 2-амино-5-(1-бром- 2-арил-2-оксоэтилиден)-4-оксо-1H-4,5-дигидрофуран-3-карбоновых кислот. Установлено, что соединение с 4-хлорфенильным заместителем обладает наиболее выраженным противогрибковым действием (МПК50 — 3,9 мг/л, МПК90 — 7,8 мг/л), что превышает активность флуконазола, в том числе, в отношении Candida auris, что дает основание для дальнейшего изучения данного вещества.
- 1 February 2025
- Published by Pleiades Publishing Ltd in Russian Journal of General Chemistry
- Vol. 95 (2) , 291-300
Synthesis and Study of Antimicrobial Activity of Reaction Products of Substituted 3-Thienylimino-3H-furan-2-ones with Substituted Hydrazines and Hydrazides
A method was proposed for the synthesis of new biologically active compounds based on substituted 3-thienylimino-3H-furan-2-ones with various hydrazines and hydrazides. Synthesis in the presence of one equivalent of hydrazine or hydrazide or their excess was considered. The obtained compounds were found to possess pronounced antimicrobial activity against strains of Candida albicans NCTC 885-653, Staphylococcus aureus ATCC 6538-P, and Escherichia coli ATCC 25922. The acute toxicity (LD50) of the obtained compounds is >1500 mg/kg and they belong to practically nontoxic compounds.
- 1 February 2025
- Published by Pleiades Publishing Ltd in Russian Journal of General Chemistry
- Vol. 95 (2) , 291-300
Synthesis and Study of Antimicrobial Activity of Reaction Products of Substituted 3-Thienylimino-3H-furan-2-ones with Substituted Hydrazines and Hydrazides
A method was proposed for the synthesis of new biologically active compounds based on substituted 3-thienylimino-3H-furan-2-ones with various hydrazines and hydrazides. Synthesis in the presence of one equivalent of hydrazine or hydrazide or their excess was considered. The obtained compounds were found to possess pronounced antimicrobial activity against strains of Candida albicans NCTC 885-653, Staphylococcus aureus ATCC 6538-P, and Escherichia coli ATCC 25922. The acute toxicity (LD50) of the obtained compounds is >1500 mg/kg and they belong to practically nontoxic compounds.
- Open Access
- 8 December 2024
- Published by Altai State University in Chemistry of plant raw material
- No. 4,p. 287-296
ANTIMICROBIAL ACTIVITY OF SECONDARY METABOLITES ISOLATED FROM THE TOADFLAX HERB (LINARIA VULGARIS MILL.)
The widespread and inappropriate use of antibiotics has led to the emergence of new multidrug-resistant (MDR) strains of microorganisms, rendering many currently available drugs ineffective. Thus, there is a growing need to develop new antimicrobial agents that can reduce antibiotic use and counter the development of resistance. According to previous studies, polyphenols are able to exhibit pronounced antimicrobial activity. Linaria vulgaris Mill. is one of the promising representatives of the genus Linaria, the chemical composition of which is represented by such classes of metabolites as phenolic acids, flavonoids, phenolic glycosides, alkaloids and iridoids. As a result of the present study, 6 compounds belonging to the classes of flavonoids and phenolic acids were isolated from the herb L. vulgaris, and their activity against S. aureus, C. albicans and E. coli was studied. Among all the isolated compounds, p-coumaric acid showed the greatest antimicrobial activity, the minimum inhibitory concentration (MIC) of which was 250, 500 and 1000 μg/ml against C. albicans, E. coli and S. aureus, respectively.
- 8 December 2024
- Published by Altai State University in Chemistry of plant raw material
- No. 4,p. 287-296
Open AccessANTIMICROBIAL ACTIVITY OF SECONDARY METABOLITES ISOLATED FROM THE TOADFLAX HERB (LINARIA VULGARIS MILL.)
The widespread and inappropriate use of antibiotics has led to the emergence of new multidrug-resistant (MDR) strains of microorganisms, rendering many currently available drugs ineffective. Thus, there is a growing need to develop new antimicrobial agents that can reduce antibiotic use and counter the development of resistance. According to previous studies, polyphenols are able to exhibit pronounced antimicrobial activity. Linaria vulgaris Mill. is one of the promising representatives of the genus Linaria, the chemical composition of which is represented by such classes of metabolites as phenolic acids, flavonoids, phenolic glycosides, alkaloids and iridoids. As a result of the present study, 6 compounds belonging to the classes of flavonoids and phenolic acids were isolated from the herb L. vulgaris, and their activity against S. aureus, C. albicans and E. coli was studied. Among all the isolated compounds, p-coumaric acid showed the greatest antimicrobial activity, the minimum inhibitory concentration (MIC) of which was 250, 500 and 1000 μg/ml against C. albicans, E. coli and S. aureus, respectively.
- Open Access
- 13 November 2024
- Published by ECO-Vector LLC in Perm Medical Journal
- Vol. 41 (5) , 138-146
Study of anti-inflammatory activity and acute toxicity indicators of new silver salt of pyrazole-3-carboxamide
Objective. To study the anti-inflammatory activity and some toxicological indicators of the new derivative of pyrazole-3-carboxamide SSP. Materials and methods. To assess the biological activity of the compound, its anti-inflammatory effect was studied in the model of acute inflammatory edema caused by sub-plantar injection of carrageenan solution into a rat`s hind leg. The duration effect was assessed by the intensity of suppression of the inflammatory response in relation to the control level. In order to study the safety of the substance, the local irritant effect was determined when applied cutaneously in the experiments on rats. The severity of the irritant effect was assessed by the erythema degree, the amount of edema and the increase in local skin temperature. In addition, acute toxicity of the substance under study was determined. The test compound and reference drugs were applied to the skin. Results. The study of acute toxicity of the compound SSP and the reference drug nystatin when applied cutaneously to rats showed that LD50 of both substances was more than 2500,0 mg/kg. Indicators of the degree of local irritating effect of the drugs demonstrate its absence. At the same time, the studied SSP compound has no anti-inflammatory effect administered either orally or cutaneously. Conclusions. The data obtained allow us to classify the new silver salt of pyrazol-3-carboxamide SSP as a class 5 non-toxic substance. The studied SSP compound has no local irritant effect and does not demonstrate anti-inflammatory activity in the carrageenan inflammation model.
- 13 November 2024
- Published by ECO-Vector LLC in Perm Medical Journal
- Vol. 41 (5) , 138-146
Open AccessStudy of anti-inflammatory activity and acute toxicity indicators of new silver salt of pyrazole-3-carboxamide
Objective. To study the anti-inflammatory activity and some toxicological indicators of the new derivative of pyrazole-3-carboxamide SSP. Materials and methods. To assess the biological activity of the compound, its anti-inflammatory effect was studied in the model of acute inflammatory edema caused by sub-plantar injection of carrageenan solution into a rat`s hind leg. The duration effect was assessed by the intensity of suppression of the inflammatory response in relation to the control level. In order to study the safety of the substance, the local irritant effect was determined when applied cutaneously in the experiments on rats. The severity of the irritant effect was assessed by the erythema degree, the amount of edema and the increase in local skin temperature. In addition, acute toxicity of the substance under study was determined. The test compound and reference drugs were applied to the skin. Results. The study of acute toxicity of the compound SSP and the reference drug nystatin when applied cutaneously to rats showed that LD50 of both substances was more than 2500,0 mg/kg. Indicators of the degree of local irritating effect of the drugs demonstrate its absence. At the same time, the studied SSP compound has no anti-inflammatory effect administered either orally or cutaneously. Conclusions. The data obtained allow us to classify the new silver salt of pyrazol-3-carboxamide SSP as a class 5 non-toxic substance. The studied SSP compound has no local irritant effect and does not demonstrate anti-inflammatory activity in the carrageenan inflammation model.
- Open Access
- 2 October 2024
- Published by Cardiology Research Institute in Siberian Journal of Clinical and Experimental Medicine
- Vol. 39 (3) , 150-155
Antifungal activity’s study of the of new derivatives of pyrrolo[3,4-c]pyrazol-3-ones and pyrazol-3- carboxamides in the biofilm model of Candida spp.
The search for new antifungal drugs is current interest due to the wide spread of fungal infections. To simulate the antifungal effect of new promising compounds with high antifungal activity in planktonic culture in clinical practice, it is necessary to study their effect on the biofilm of micromycetes.Aim: To study the antifungal activity of new promising representatives of silver salts of pyrazoles and their condensed systems under conditions of biofilm formation.Material and Methods. To study the antifungal activity of silver salts I and II, the micromethod of two-fold serial dilutions was used. Activity against a typical and 14 clinical highly virulent isolates of C. albicans was studied. The study of the antimycotic activity of substances under biofilm conditions was carried out using resazurin to quantify the degree of biofilm formation. The minimum inhibitory concentrations for biofilms were calculated (sMIC50 - the concentration of the antifungal substance at which a 50% decrease in fluorescence is observed compared to the positive control).Results and Discussion. It was shown that the antifungal effect of the studied compounds in biofilm culture of clinical strains of Candida spp. is significantly lower than in planktonic culture. High antifungal activity of the silver salt of pyrazole-3- carboxamide in planktonic and biofilm cultures of resistant strains of Candida albicans, exceeding the effect of the reference drug fluconazole by 2.8–11.2 times, was revealed.Conclusion. A promising pyrazole-3-carboxamide derivative has been identified that effectively inhibits the growth of Candida albicans biofilms, which can be recommended for further study.
- 2 October 2024
- Published by Cardiology Research Institute in Siberian Journal of Clinical and Experimental Medicine
- Vol. 39 (3) , 150-155
Open AccessAntifungal activity’s study of the of new derivatives of pyrrolo[3,4-c]pyrazol-3-ones and pyrazol-3- carboxamides in the biofilm model of Candida spp.
The search for new antifungal drugs is current interest due to the wide spread of fungal infections. To simulate the antifungal effect of new promising compounds with high antifungal activity in planktonic culture in clinical practice, it is necessary to study their effect on the biofilm of micromycetes.Aim: To study the antifungal activity of new promising representatives of silver salts of pyrazoles and their condensed systems under conditions of biofilm formation.Material and Methods. To study the antifungal activity of silver salts I and II, the micromethod of two-fold serial dilutions was used. Activity against a typical and 14 clinical highly virulent isolates of C. albicans was studied. The study of the antimycotic activity of substances under biofilm conditions was carried out using resazurin to quantify the degree of biofilm formation. The minimum inhibitory concentrations for biofilms were calculated (sMIC50 - the concentration of the antifungal substance at which a 50% decrease in fluorescence is observed compared to the positive control).Results and Discussion. It was shown that the antifungal effect of the studied compounds in biofilm culture of clinical strains of Candida spp. is significantly lower than in planktonic culture. High antifungal activity of the silver salt of pyrazole-3- carboxamide in planktonic and biofilm cultures of resistant strains of Candida albicans, exceeding the effect of the reference drug fluconazole by 2.8–11.2 times, was revealed.Conclusion. A promising pyrazole-3-carboxamide derivative has been identified that effectively inhibits the growth of Candida albicans biofilms, which can be recommended for further study.
- 30 September 2024
- Published by Technomed Holdings LLC in "Medical & Pharmaceutical Journal "Pulse"
DEVELOPMENT OF AN EXPERIMENTAL DOSAGE FORM FOR TOPICAL USE WITH ANTIFUNGAL ACTION
Currently, mycoses are one of the urgent health problems. According to WHO, up to 1/3 of the world's population suffers from fungal pathologies. Currently, fungal infections are becoming increasingly difficult to treat, which is associated both with the identification of new species of fungi that were previously considered non-pathogenic, and with the development of resistance of pathogens to available medicines. The problem of mycoses is becoming more urgent due to the variety of pathways of transmission of pathogens and their high resistance in the external environment, changes in the immune response of the human body. Therefore, it is so important to expand the range and constantly improve the compositions and forms of antifungal agents. The substance of the silver salt pyrazole-3-carboxamide (SSP) synthesized in PGFA showed antifungal activity, which allowed it to be included in the experimental mild dosage form. The purpose of this study is to develop an experimental mild dosage form based on the silver salt of pyrazole–3-carboxamide for topical use in candidiasis dermatomycosis and to evaluate its antifungal activity. Materials and methods. The pharmacologically active component is the pharmaceutical substance of the silver salt N-{4-[(1,3-thiazole-2-yl)sulfamoyl]phenyl}-1-phenyl-5-(4-ethoxyphenyl)pyrazole-3-carboxamide. The antifungal activity of the compound was studied by double serial dilutions in a liquid nutrient medium in relation to reference strains of fungi of the genus Candida: Candida albicans NCTC 885-653, Candida krusei RCPGU-1472/310, Candida glabrata RCPGU-1485/47. To determine the antifungal activity of an experimental mild dosage form in relation to a typical strain of fungi of the genus Candida, a three-nesting variant of the agar diffusion method was used. Statistical processing of the results of chemical studies was carried out according to generally accepted methods using standard EXCEL computer programs. Results and discussion. As a result of the conducted research, the composition of an experimental mild dosage form based on the silver salt of pyrazole-3-carboxamide has been substantiated and developed. A technology for the manufacture of ointment has been developed to ensure the quality of the dosage form, its therapeutic activity and stability. Conclusion. Based on technological and microbiological studies, an experimental mild dosage form based on the silver salt of pyrazole-3-carboxamide has been developed with the aim of further introduction into medical practice for the local treatment of dermatomycosis after appropriate studies.
- 30 September 2024
- Published by Technomed Holdings LLC in "Medical & Pharmaceutical Journal "Pulse"
DEVELOPMENT OF AN EXPERIMENTAL DOSAGE FORM FOR TOPICAL USE WITH ANTIFUNGAL ACTION
Currently, mycoses are one of the urgent health problems. According to WHO, up to 1/3 of the world's population suffers from fungal pathologies. Currently, fungal infections are becoming increasingly difficult to treat, which is associated both with the identification of new species of fungi that were previously considered non-pathogenic, and with the development of resistance of pathogens to available medicines. The problem of mycoses is becoming more urgent due to the variety of pathways of transmission of pathogens and their high resistance in the external environment, changes in the immune response of the human body. Therefore, it is so important to expand the range and constantly improve the compositions and forms of antifungal agents. The substance of the silver salt pyrazole-3-carboxamide (SSP) synthesized in PGFA showed antifungal activity, which allowed it to be included in the experimental mild dosage form. The purpose of this study is to develop an experimental mild dosage form based on the silver salt of pyrazole–3-carboxamide for topical use in candidiasis dermatomycosis and to evaluate its antifungal activity. Materials and methods. The pharmacologically active component is the pharmaceutical substance of the silver salt N-{4-[(1,3-thiazole-2-yl)sulfamoyl]phenyl}-1-phenyl-5-(4-ethoxyphenyl)pyrazole-3-carboxamide. The antifungal activity of the compound was studied by double serial dilutions in a liquid nutrient medium in relation to reference strains of fungi of the genus Candida: Candida albicans NCTC 885-653, Candida krusei RCPGU-1472/310, Candida glabrata RCPGU-1485/47. To determine the antifungal activity of an experimental mild dosage form in relation to a typical strain of fungi of the genus Candida, a three-nesting variant of the agar diffusion method was used. Statistical processing of the results of chemical studies was carried out according to generally accepted methods using standard EXCEL computer programs. Results and discussion. As a result of the conducted research, the composition of an experimental mild dosage form based on the silver salt of pyrazole-3-carboxamide has been substantiated and developed. A technology for the manufacture of ointment has been developed to ensure the quality of the dosage form, its therapeutic activity and stability. Conclusion. Based on technological and microbiological studies, an experimental mild dosage form based on the silver salt of pyrazole-3-carboxamide has been developed with the aim of further introduction into medical practice for the local treatment of dermatomycosis after appropriate studies.